Vivos Therapeutics, Inc.VVOSNASDAQ
Loading
Free Cash Flow Growth AcceleratingAccelerating
Percentile Rank85
5Y CAGR-8.7%
Year-over-Year Change
Year-over-year free cash flow growth rate
5Y CAGR
-8.7%/yr
Long-term compound
Percentile
P85
Within normal range
vs 5Y Ago
0.6x
Contraction
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q3 2025 | 23.38% |
| Q2 2025 | -12.36% |
| Q1 2025 | -22.25% |
| Q4 2024 | 21.91% |
| Q3 2024 | -27.93% |
| Q2 2024 | -16.54% |
| Q1 2024 | 8.44% |
| Q4 2023 | 1.39% |
| Q3 2023 | 4.83% |
| Q2 2023 | 17.84% |
| Q1 2023 | -18.06% |
| Q4 2022 | 46.15% |
| Q3 2022 | -15.00% |
| Q2 2022 | 16.69% |
| Q1 2022 | -37.68% |
| Q4 2021 | -0.13% |
| Q3 2021 | 10.11% |
| Q2 2021 | -21.40% |
| Q1 2021 | -11.02% |
| Q4 2020 | -483.31% |
| Q3 2020 | 36.85% |
| Q2 2020 | -128.04% |
| Q1 2020 | 73.38% |
| Q4 2019 | -115.00% |
| Q3 2019 | 49.87% |
| Q2 2019 | 0.00% |
| Q1 2019 | 0.00% |